Under the deal, Fisher will provide cryogenic storage and distribution for Pluristem’s PLacental eXpanded (PLX) cells.
The Israel-based contract manufacturing organisation (CMO) is currently providing cells to local sites as well as in Europe, India and the US. It now works with a range of indications, including intermittent claudication, muscle regeneration, critical limb ischemia, Buerger's disease and acute radiation syndrome.
"As we expand our roster of clinical trials for our PLX cell therapies for several indications, we needed a reliable leader in cell therapy distribution,” CEO Zami Aberman said. “Fisher BioServices was the clear choice for us because they are the world's leader in biological materials handling and have supported hundreds of clinical trials.”
Pre-clinical studies in the acute myocardial infarction (heart attack), lung disease, and bone marrow disease arenas have also been earmarked as future growth areas for Pluristem, as they “collectively represent multibillion dollar treatment markets.”